HemaSphere (Aug 2023)
S194: TECLISTAMAB (TEC) + NIROGACESTAT (NIRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): THE PHASE 1B MAJESTEC-2 STUDY
- Fritz Offner,
- Olivier Decaux,
- Cyrille Hulin,
- Sébastien Anguille,
- Anne Sophie Michallet,
- Luciano Costa,
- Cyrille Touzeau,
- Kevin Boyd,
- Deeksha Vishwamitra,
- Yue Guo,
- Zhuolu Niu,
- Julie Larsen,
- Lingling Chen,
- Arnob Banerjee,
- Jenna Goldberg,
- Jeffrey Matous
Affiliations
- Fritz Offner
- 1 University Hospital Ghent, Ghent, Belgium
- Olivier Decaux
- 2 Centre Hospitalier Universitaire de Rennes, Rennes, France
- Cyrille Hulin
- 3 Hôpital Haut Leveque, University Hospital, Pessac, France
- Sébastien Anguille
- 4 Vaccine and Infectious Disease Institute, University of Antwerp and the Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium
- Anne Sophie Michallet
- 5 Centre Hospitalier Lyon Sud, Hospices Civils, Pierre Bénite, France
- Luciano Costa
- 6 University of Alabama at Birmingham, Birmingham, United States
- Cyrille Touzeau
- 7 Centre Hospitalier Universitaire de Nantes, Nantes, France
- Kevin Boyd
- 8 The Royal Marsden Hospital, London, United Kingdom
- Deeksha Vishwamitra
- 9 Janssen Research & Development, Spring House, United States
- Yue Guo
- 9 Janssen Research & Development, Spring House, United States
- Zhuolu Niu
- 10 Janssen Research & Development, Shanghai, China
- Julie Larsen
- 11 Janssen Research & Development, Los Angeles, United States
- Lingling Chen
- 9 Janssen Research & Development, Spring House, United States
- Arnob Banerjee
- 9 Janssen Research & Development, Spring House, United States
- Jenna Goldberg
- 12 Janssen Research & Development, Raritan, United States
- Jeffrey Matous
- 13 Colorado Blood Cancer Institute and Sarah Cannon Research Institute, Denver, United States
- DOI
- https://doi.org/10.1097/01.HS9.0000967688.12579.64
- Journal volume & issue
-
Vol. 7
p. e1257964
Abstract
No abstracts available.